Clofibrate in the Treatment of the Non-hemolytic Hyperbilirubinemia in Preterm Neonates in Western Iran

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 213

This Paper With 5 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IRJN-12-3_008

تاریخ نمایه سازی: 2 شهریور 1400

Abstract:

Background: No studies, to the best of our knowledge, have been conducted on the effect of Clofibrate in reducing hyperbilirubinemia in preterm infants. Therefore, this study aimed at investigating the therapeutic effect of Clofibrate in treating hyperbilirubinemia of preterm neonates. Methods: This clinical trial was performed from April ۴ to December ۲۰, ۲۰۱۹, on neonates in Hamadan in western Iran. The allocation remained concealed to the researcher, neonates’ parents, and analyzer during the study. A dose of Clofibrate of ۲۵ kg/mg was given on the first day of hospitalization. The neonates in the placebo group received the oral placebo ۲۵ kg/mg in the same way as the oral Clofibrate. The data were analyzed using SPSS ۱۶ with P-value < ۰.۰۵. Results: No statistically significant difference was observed in the baseline characteristics of the two groups based on the neonate’s age and gender, delivery method, and gestational age. The prescription of Clofibrate significantly reduced the duration of hospitalization (p= ۰.۰۰۲) and phototherapy (p= ۰.۰۰۱). Prescribing a single oral dose of Clofibrate (۲۵ mg/Kg) along with phototherapy in preterm neonates significantly reduced total serum bilirubin levels at ۲۴ and ۴۸ hours after treatment compared with phototherapy alone (p= ۰.۰۰۱). However, this association was not significant in admission (p= ۰.۰۹۵). Conclusion: The findings of this study showed the effect of Clofibrate in treating hyperbilirubinemia of preterm neonates. In addition, prescribing Clofibrate significantly reduced the duration of hospitalization and phototherapy.    

Authors

fatemeh eghbalian

Hamadan University of Medical Sciences, Hamadan, Iran

Ensiyeh Jenabi

Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

Elham Hatami

Hamadan University of Medical Sciences, Hamadan, Iran

Behnaz Basiri

Hamadan University of Medical Sciences, Hamadan, Iran

Katayoun Derakhshandeh

Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

Nasrollah Pezeshki

Hamadan University of Medical Sciences, Hamadan, Iran

Elham Khanlarzadeh

Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Torabi Z, Eskandarzadeh A, Ahmadiafshar A. The effect of clofibrate ...
  • Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, ...
  • Méndez-Sánchez N, Vítek L, Aguilar-Olivos NE, Uribe M. Bilirubin as ...
  • Shapiro SM, Riordan SM. Review of bilirubin neurotoxicity II: preventing ...
  • Gholitabar M, McGuire H, Rennie J, Manning D, Lai R. ...
  • Hamidi M, Zamanzad B, Mesripour A. Comparing the effect of ...
  • Eghbalian F, Pourhossein A, Zandevakili H. Effect of clofibrate in ...
  • Kumar P, Adhisivam B, Bhat BV. Clofibrate as an adjunct ...
  • Fallah R, Islami Z, Lotfi SR. Single dose of ۵۰ ...
  • Eghbalian F, Monsef F, Alam Ghomi N, Monsef A. Effect ...
  • Zahed Pasha Y, Alizadeh-Tabari S, Zahed Pasha E, Zamani M. ...
  • Lindenbaum A, Delaporte B, Benattar C, Dehan M, Magny JF, ...
  • نمایش کامل مراجع